메뉴 건너뛰기




Volumn 198, Issue 8, 2017, Pages 3023-3028

Cutting edge: Innate immune augmenting vesicular stomatitis virus expressing zika virus proteins confers protective immunity

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN E, FLAVIVIRUS; VIRUS VACCINE;

EID: 85017341081     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1602180     Document Type: Article
Times cited : (43)

References (15)
  • 2
    • 84985987120 scopus 로고    scopus 로고
    • Zika virus: Implications for public health
    • Focosi, D., F. Maggi, and M. Pistello. 2016. Zika virus: implications for public health. Clin. Infect. Dis. 63: 227-233.
    • (2016) Clin. Infect. Dis. , vol.63 , pp. 227-233
    • Focosi, D.1    Maggi, F.2    Pistello, M.3
  • 3
    • 84964276686 scopus 로고    scopus 로고
    • Zika virus and birth defects-reviewing the evidence for causality
    • Rasmussen, S. A., D. J. Jamieson, M. A. Honein, and L. R. Petersen. 2016. Zika virus and birth defects-reviewing the evidence for causality. N. Engl. J. Med. 374: 1981-1987.
    • (2016) N. Engl. J. Med. , vol.374 , pp. 1981-1987
    • Rasmussen, S.A.1    Jamieson, D.J.2    Honein, M.A.3    Petersen, L.R.4
  • 5
    • 84994059378 scopus 로고    scopus 로고
    • Zika virus: Immunity and vaccine development
    • Pierson, T. C., and B. S. Graham. 2016. Zika virus: immunity and vaccine development. Cell 167: 625-631.
    • (2016) Cell , vol.167 , pp. 625-631
    • Pierson, T.C.1    Graham, B.S.2
  • 6
    • 84971641047 scopus 로고    scopus 로고
    • Scoping review of the Zika virus literature
    • Waddell, L. A., and J. D. Greig. 2016. Scoping review of the Zika virus literature. PLoS One 11: e0156376.
    • (2016) PLoS One , vol.11 , pp. e0156376
    • Waddell, L.A.1    Greig, J.D.2
  • 7
    • 0038013205 scopus 로고
    • The antibody response to smallpox vaccination as measured by a tissue culture plaque method
    • Cutchins, E., J. Warren, and W. P. Jones. 1960. The antibody response to smallpox vaccination as measured by a tissue culture plaque method. J. Immunol. 85: 275-283.
    • (1960) J. Immunol. , vol.85 , pp. 275-283
    • Cutchins, E.1    Warren, J.2    Jones, W.P.3
  • 8
    • 80054989227 scopus 로고    scopus 로고
    • Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent
    • Heiber, J. F., and G. N. Barber. 2011. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. J. Virol. 85: 10440-10450.
    • (2011) J. Virol. , vol.85 , pp. 10440-10450
    • Heiber, J.F.1    Barber, G.N.2
  • 10
    • 0027478991 scopus 로고
    • Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein
    • Konishi, E., and P. W. Mason. 1993. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J. Virol. 67: 1672-1675.
    • (1993) J. Virol. , vol.67 , pp. 1672-1675
    • Konishi, E.1    Mason, P.W.2
  • 11
    • 58249118005 scopus 로고    scopus 로고
    • Recombinant vesicular stomatitis virus-based West Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent West Nile virus strain LSU-AR01
    • Iyer, A. V., B. Pahar, M. J. Boudreaux, N. Wakamatsu, A. F. Roy, V. N. Chouljenko, A. Baghian, C. Apetrei, P. A. Marx, and K. G. Kousoulas. 2009. Recombinant vesicular stomatitis virus-based West Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent West Nile virus strain LSU-AR01. Vaccine 27: 893-903.
    • (2009) Vaccine , vol.27 , pp. 893-903
    • Iyer, A.V.1    Pahar, B.2    Boudreaux, M.J.3    Wakamatsu, N.4    Roy, A.F.5    Chouljenko, V.N.6    Baghian, A.7    Apetrei, C.8    Marx, P.A.9    Kousoulas, K.G.10
  • 12
    • 0036140461 scopus 로고    scopus 로고
    • Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease
    • Fernandez, M., M. Porosnicu, D. Markovic, and G. N. Barber. 2002. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 76: 895-904.
    • (2002) J. Virol. , vol.76 , pp. 895-904
    • Fernandez, M.1    Porosnicu, M.2    Markovic, D.3    Barber, G.N.4
  • 13
    • 0036315015 scopus 로고    scopus 로고
    • Adding genes to the RNA genome of vesicular stomatitis virus: Positional effects on stability of expression
    • Wertz, G. W., R. Moudy, and L. A. Ball. 2002. Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression. J. Virol. 76: 7642-7650.
    • (2002) J. Virol. , vol.76 , pp. 7642-7650
    • Wertz, G.W.1    Moudy, R.2    Ball, L.A.3
  • 14
    • 0033646858 scopus 로고    scopus 로고
    • Vesicular stomatitis virus (VSV) therapy of tumors
    • Balachandran, S., and G. N. Barber. 2000. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50: 135-138.
    • (2000) IUBMB Life , vol.50 , pp. 135-138
    • Balachandran, S.1    Barber, G.N.2
  • 15
    • 0042208208 scopus 로고    scopus 로고
    • Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity
    • Obuchi, M., M. Fernandez, and G. N. Barber. 2003. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77: 8843-8856.
    • (2003) J. Virol. , vol.77 , pp. 8843-8856
    • Obuchi, M.1    Fernandez, M.2    Barber, G.N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.